CTOs on the Move

Bodyport

www.bodyport.com

 
Bodyport is the platform for health in the home. Understand your body on a deeper level. Predict and prevent disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Bodyport raised $11.2M on 08/11/2020

Similar Companies

Amplifon

We are the global leader in hearing solutions and services for retail expertise, customization and consumer care. Almost 12,000 professionals every day in a network of 3,700 points of sale, 3,600 service centers and 1,750 affiliates, give back the joy of hearing, feeling and living to thousands of people across the world. Being the one and only global company in our industry focused purely on hearing care services, we are able to bring seven decades of experience to every single consultation. That means striving to give our customers a premium experience by equipping our people with the necessary time, the best and exclusive tools, the latest technology and the finest training from the moment they join.

Advantica Benefits

Advantica Benefits is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Caloptima Health Partnership

Caloptima Health Partnership is a Orange, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Systems Assessment and Research

Systems Assessment and Research is a Lanham, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.